Print

Print


Dopaminomimetic psychosis in Parkinson's disease patients:
diagnosis and treatment.

Dopaminomimetic agents, which were rationally designed to reverse dopamine
deficits in the substantia nigra and ventral tegmental area of the
parkinsonian midbrain, effectively attenuate deficits in motor and
non-motor behavior thought to be elicited by dopamine deficiencies in the
striatal and frontal limbic regions, respectively.

On the other hand, dopaminomimetic medications may also induce
perturbations in postsynaptic peptides, causing dopaminergic hypersensitivity.

Drug-induced chronic dopaminomimetic psychosis afflicts about one-fifth of
PD patients on dopaminergic regimens.

Although the long-held mechanism for psychosis in PD is excessive
stimulation of mesocorticolimbic dopamine receptors, interactions between
dopamine and serotonin, as well as participation of serotonin-modulated
GABAergic neurons may also contribute to the pathophysiology.

Reduction or withdrawal of anticholinergic agents, amantadine, and dopamine
precursors or agonists constitutes a first approach to the problem but is
often insufficient.

Unfortunately, typical antipsychotic agents such as haloperidol, which
selectively antagonizes dopamine D-2 receptors, can induce extrapyramidal
syndromes such as tardive parkinsonism.

On the other hand, emerging atypical neuroleptics such as clozapine,
quetiapine, and olanzapine, which antagonize 5HT-2A receptors (among
others), inhibit D-2 receptors to a lesser degree and exhibit selective
binding to mesolimbic (vs. striatal) dopamine receptors.

The limbic selectivity of these agents appears to be of greater magnitude
than that typical of risperidone.

In addition, the selective antiserotonergic agent ondansetron is a
prospective therapeutic option.

The pharmacologic properties of these agents are explored.


Neurology 1999;52(7 Suppl 3):S10-3
Wolters EC
Research Institute Neurosciences VU, Department of Neurology AZVU, The
Netherlands.
PMID: 10227604, UI: 99242143

http://www.ncbi.nlm.nih.gov/PubMed/


janet paterson
52 now / 41 dx / 37 onset
snail-mail: PO Box 171  Almonte  Ontario  K0A 1A0  Canada
website: a new voice <http://www.geocities.com/SoHo/Village/6263/>
e-mail: <[log in to unmask]>